Claims
- 1. A method of inducing a venotonizing effect in a subject which comprises administering to a subject in need of such treatment a venotonizing effective amount of a compound of formula I, ##STR6## wherein R.sub.1 is (C.sub.1-4)alkyl,
- R.sub.2 is (C.sub.1-6)alkyl or benzyl,
- R.sub.3 and R.sub.4 independently are hydrogen or (C.sub.1-4) alkyl,
- R.sub.5 is hydrogen or bromine,
- R.sub.6 and R.sub.7 are each hydrogen, or
- R.sub.6 and R.sub.7 together form a single bond, or
- R.sub.6 is methoxy and R.sub.7 is hydrogen, and
- R.sub.8 is hydrogen, methyl, or halogen of atomic number from 9 to 35,
- with the proviso that when R.sub.5 is bromine, R.sub.7 is hydrogen; in free base form or in pharmaceutically acceptable acid addition salt form.
- 2. A method according,to claim 1 in which the compound is 9,10-dihydro-9'-thia-.alpha.-ergocryptine in free base form or in pharmaceutically acceptable acid addition salt form.
- 3. A method according to claim 1 in which the compound is 9'-thia-.alpha.-ergocryptinine or 9'-thia-.alpha.-ergocryptine in free base form or in pharmaceutically acceptable acid addition salt form.
- 4. A method according to claim 1 in which the compound is 9'-thia-ergotamine or 9'-thia-ergotaminine in free base form or in pharmaceutically acceptable acid addition salt form.
- 5. A method according to claim 1 in which the compound is 9'-thiaergocristine or 9'-thiaergocristinine in free base form or in pharmaceutically acceptable acid addition salt form.
- 6. A method according to claim 1 in which the compound is (a) 2-methyl-9,10-dihydro-9'-thia-.alpha.-ergocryptine; (b) 6-nor-6-ethyl-9,10-dihydro-9'-thia-.alpha.-ergocryptine; or (c) 9,10-dihydro-9'-thia-ergotamine in free base form or in pharmaceutically acceptable acid addition salt form.
- 7. A method according to claim 1 in which from 0.01 mg to 10 mg per kg of animal body weight of the compound is administered daily.
- 8. A method according to claim 1 in which 5 to 100 mg of the compound is administered daily.
- 9. A method according to claim 1 in which 1 to 50 mg of the compound is administered orally per unit dose.
- 10. A method of treating orthostatic hypotens in a subject in need of such treatment which comprises administering to the subject and effective amount for the treatment of orthostatic hypotension of a compound of formula I, ##STR7## wherein R.sub.1 is (C.sub.1-4)alkyl,
- R.sub.2 is (C.sub.1-6)alkyl or benzyl,
- R.sub.3 and R.sub.4 independently are hydrogen or (C.sub.1-4)alkyl,
- R.sub.5 is hydrogen or bromine,
- R.sub.6 and R.sub.7 are each hydrogen, or
- R.sub.6 and R.sub.7 together form a single bond, or
- R.sub.6 is methoxy and R.sub.7 is hydrogen, and
- R.sub.8 is hydrogen, methyl, or halogen of atomic number from 9 to 35,
- with the proviso that when R.sub.5 is bromine, R.sub.7 is hydrogen; in free base form or in pharmaceutically acceptable acid addition salt form.
- 11. A method according to claim 10 in which the compound is 9,10-dihydro-9'-thia-.alpha.-ergocryptine in free base form or in pharmaceutically acceptable acid addition salt form.
- 12. A method according to claim 10 in which the compound is 9'-thia-.alpha.-ergocryptinine or 9'-thia-.alpha.-ergocryptine in free base form or in pharmaceutically acceptable acid addition salt form.
- 13. A method according to claim 10 in which the compound is 9'-thia-ergotamine or 9'-thia-ergotaminine in free base form or in pharmaceutically acceptable acid addition salt form.
- 14. A method according to claim 10 in which the compound is 9'-thiaergocristine or 9'-thiaergocristinine in free base form or in pharmaceutically acceptable acid addition salt form.
- 15. A method according to claim 10 in which the compound is (a) 2-methyl-9,10-dihydro-9'thia-.alpha.-ergocryptine; (b) 6-nor-6-ethyl-9,10-dihydro-9'-thia-.alpha.-ergocryptine; or (c) 9,10-dihydro-9'-thia-ergotamine in free base form or in pharmaceutically acceptable acid addition salt form.
- 16. A method according to claim 10 in which from 0.01 mg to 10 mg per kg of animal body weight of the compound is administered daily.
- 17. A method according to claim 10 in which 5 to 100 mg of the compound is adminstered daily.
- 18. A method according to claim 10 in which 1 to 50 mg of the compound is administered orally per unit dose.
Priority Claims (1)
Number |
Date |
Country |
Kind |
5104/81 |
Aug 1981 |
CHX |
|
Parent Case Info
This is a division of application Ser. No. 751,272, filed July 2, 1985, now U.S. Pat. No. 4,681,880, which in turn is a division of application Ser. No. 404,832, filed Aug. 3, 1982, now U.S. Pat. No. 4,542,135.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4609657 |
Stadler et al. |
Sep 1986 |
|
4609731 |
Juyec et al. |
Sep 1986 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
2109795 |
Jun 1983 |
GBX |
Non-Patent Literature Citations (1)
Entry |
Pharmacology & Clinical Pharmacology of Dihydro-Ergotamine, Berde & Schild, Springer-Verlag, pp. 97-103. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
751272 |
Jul 1985 |
|
Parent |
404832 |
Aug 1982 |
|